To confirm that APOBEC3A’s DNA-damaging effects depend on its deaminase activity across different bladder cancer subtypes, we compared wild-type and deaminase-inactive APOBEC3A variants in the RT112/84 cells, a luminal cell line with low baseline genome instability (29,30). Here, APOBEC3A is linked to urinary bladder cancer.